Growth-hormone research · Research peptide fragment
Also known as AOD 9604
A modified fragment related to human growth hormone studied in metabolic and weight-related research. It is not an FDA-approved drug.[1]
A clinical benefit and a complete safety picture have not been established for the defined material or use reviewed here.
Reviewed Jul 22, 2026 · U.S.-focused reference profile
Read the context, not only the compound name. Evidence and status can change with the form, route, population, and use. This profile does not assess individual suitability.
Orientation
Start with identity and research context. Similar names do not establish equivalent products or evidence.
Published research or product contexts. These are not personal indications.
Evidence can change with chemical form, formulation, route, ingredients, and manufacturing. A brand, salt, fragment, or cosmetic ingredient may not represent the same evidence.
What is known
A clinical benefit and a complete safety picture have not been established for the defined material or use reviewed here. This is a description, not a rating or recommendation.
Body-composition and secretagogue research
Publicly described human studies have not established an FDA-approved indication or a reliable clinical benefit. FDA states that available safety information is limited.
The clinical evidence base, product identity, long-term effects, and relationship of reported events to the compound remain uncertain. Online or compounded products have not undergone FDA premarket review.
The development rationale came from laboratory and animal work on growth-hormone fragments and fat metabolism. Those results do not establish weight loss or safety in humans.[1]
More human evidence does not automatically transfer to a different product, route, population, or purpose. Limited evidence does not prove no biological activity; it means the relevant clinical question is not established by the reviewed material.
What needs caution
Known published concerns and unanswered questions are kept separate so absence of evidence is never presented as reassurance.
FDA notes immunogenicity, impurity, and API-characterization concerns and reports that serious adverse events have occurred in people receiving AOD-9604, while causality could not be determined from the available information.
Research or cosmetic products may add identity, strength, purity, sterility, contamination, or formulation concerns. This is separate from the evidence about the compound itself.Source [1]The clinical evidence base, product identity, long-term effects, and relationship of reported events to the compound remain uncertain. Online or compounded products have not undergone FDA premarket review.
Human outcomes, long-term safety, formulation identity, and product consistency remain limited or unresolved in the cited material.Source [1]Common effects, important warnings, product-quality concerns, and evidence gaps are different kinds of information. A risk in one product label may not apply to every formulation; an uncertainty proves neither safety nor harm.
Match the product
Form describes the specific product; route describes how it reaches the body. These are sourced descriptions, not instructions.
No FDA-approved formulation or route exists. Experimental and marketed research preparations should not be treated as approved medicines.
No FDA-approved route exists. Research-route descriptions vary and are not instructions for use.
U.S. product context
No FDA-approved medicine was identified for this defined material. Research findings and products sold outside reviewed trials should not be treated as approval.
Status applies to a product, formulation, route, population, and use. It does not apply to a name in the abstract.
AOD-9604 is not an FDA-approved drug. FDA has identified safety and characterization concerns for its proposed use in compounding.
Specific form or route not separately published in this record.View sourceTake it forward
Organize a conversation with a qualified professional without creating a treatment recommendation, dose, or protocol.
Trace the record
Each source supports the section that cites it; publication does not imply endorsement or suitability.
FDA: Certain bulk drug substances may present significant safety risks
U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks.
U.S. Food and Drug Administration · Published Jul 22, 2026 · Accessed Jul 22, 2026 · Regulatory source
Open sourceIdentity, human evidence, laboratory and animal findings, risks, uncertainty, and U.S. product status are shown separately. Missing information stays marked as unpublished instead of being inferred.
